Ultragenyx Pharmaceu (RARE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2019 | 12-2018 | 12-2017 | 12-2016 | 12-2015 | |
| Sales | 103,714 | 51,495 | 2,612 | 133 | 0 |
| Cost of Goods | 9,008 | 1,146 | 1 | N/A | N/A |
| Gross Profit | 94,706 | 50,349 | 2,611 | 133 | N/A |
| Operating Expenses | 518,887 | 421,868 | 331,554 | 248,140 | 147,738 |
| Operating Income | -424,173 | -371,373 | -328,942 | -248,007 | -147,738 |
| Interest Expense | 1,135 | 0 | 0 | 0 | 0 |
| Other Income | 25,864 | 174,276 | 10,604 | 2,168 | 2,120 |
| Pre-tax Income | -399,444 | -197,097 | -318,338 | -245,839 | -145,618 |
| Income Tax | 3,283 | 514 | -16,199 | 35 | N/A |
| Net Income Continuous | -402,727 | -197,611 | -302,139 | -245,874 | -145,618 |
| Net Income | $-402,727 | $-197,611 | $-302,139 | $-245,874 | $-145,618 |
| EPS Basic Total Ops | -7.12 | -3.97 | -7.12 | -6.21 | -3.96 |
| EPS Basic Continuous Ops | -7.12 | -3.97 | -7.12 | -6.21 | -3.96 |
| EPS Diluted Total Ops | -7.12 | -3.97 | -7.12 | -6.21 | -3.96 |
| EPS Diluted Continuous Ops | -7.12 | -3.97 | -7.12 | -6.21 | -3.96 |
| EPS Diluted Before Non-Recurring Items | -7.36 | N/A | N/A | N/A | N/A |
| EBITDA(a) | $-421,848 | $-354,476 | $-321,411 | $-239,741 | $-140,717 |